Pyridostigmine bromide is a reversible, medium-duration acetylcholinesterase inhibitor. It is a quaternary ammonium compound that enhances cholinergic transmission by inhibiting the enzymatic degradation of acetylcholine at neuromuscular junctions and autonomic ganglia. It is a cornerstone in the symptomatic management of myasthenia gravis in the Indian clinical setting.
Adult: Myasthenia Gravis: Initial: 30-60 mg every 4-6 hours. Typical maintenance: 60 mg to 1.5 g daily in divided doses (every 3-6 hours). Dosing is highly individualized based on clinical response.
Note: Tablet should be swallowed whole with water, with or without food (taking with food may reduce GI side effects). Dosing schedule must be strictly adhered to, especially for patients with bulbar or respiratory symptoms. The interval between doses is critical (typically 4-6 hours). Do not crush or chew sustained-release formulations.
Pyridostigmine reversibly inhibits the enzyme acetylcholinesterase at cholinergic synapses. This inhibition prevents the hydrolysis of the neurotransmitter acetylcholine, leading to its accumulation and prolonged action at muscarinic and nicotinic receptors.
Pregnancy: Pregnancy Category B (US FDA). Use only if clearly needed. Myasthenia Gravis may fluctuate during pregnancy and postpartum. Close monitoring of mother and neonate is required.
Driving: May cause dizziness, blurred vision, or muscle weakness. Patients should not drive or operate machinery until they know how the drug affects them, especially when initiating or changing doses.
| Atropine / Other Anticholinergics | Mask early signs of cholinergic overdose (e.g., bradycardia, secretions) while peripheral muscarinic effects are blocked, but nicotinic effects (muscle weakness) can progress unnoticed. | Major |
| Corticosteroids (e.g., Prednisolone) | Initial exacerbation of myasthenia weakness may occur when starting steroids, requiring possible pyridostigmine dose adjustment. Long-term steroid use may improve myasthenia, reducing pyridostigmine requirement. | Moderate |
| Aminoglycosides (e.g., Gentamicin), Polymyxins, Clindamycin | May antagonize the effects of pyridostigmine at the neuromuscular junction, worsening myasthenic weakness. | Major |
| Beta-blockers (e.g., Propranolol) | Additive bradycardia and possible worsening of myasthenia. | Moderate |
| Succinylcholine | Prolonged neuromuscular blockade. | Major |
| Non-depolarizing Muscle Relaxants (e.g., Vecuronium, Rocuronium) | Pyridostigmine is used to reverse these agents, but timing is critical. Pre-existing use may alter response. | Major |
| Magnesium Salts | May antagonize the effects of pyridostigmine and worsen myasthenic weakness. | Major |